Drug intelligence / Profile preview

sotevtamab + FOLFOX

Development stage: Unknown
Lead developer: Alethia Biotherapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

**Sotevtamab + FOLFOX** is a combination regimen consisting of sotevtamab (AB-16B5), a monoclonal antibody developed as an epithelial-to-mesenchymal transition (EMT) inhibitor, and the FOLFOX chemotherapy regimen. FOLFOX consists of folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin, and is widely used in the treatment of colorectal cancer. This combination is being investigated as a neoadjuvant therapy prior to surgical resection of colorectal cancer liver metastases. Sotevtamab is intended to inhibit EMT, a process involved in cancer cell invasion and metastasis, potentially increasing the efficacy of FOLFOX chemotherapy[1][2][3][7]. The regimen is currently being investigated in a phase II clinical trial.

Brand names: none known for this combination
Other names: none known for this combination

Targets

TS (Thymidylate synthase)CLU (Clusterin)DNA

Beyond the preview

Go deeper on sotevtamab + FOLFOX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sotevtamab + FOLFOX.

Explore the full profile